Page 1 of Clinical Trials for Biological incomplete Freund s adjuvant, 72 Total Matches

Show/Hide Clinical Trials Which are Not Seeking New Volunteers

1
Completed
Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma
Last Updated: November 5, 2011
Condition(s): Melanoma (Skin)
2
Completed
Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma
Last Updated: March 14, 2012
Condition(s): Melanoma (Skin)
3
Active, not recruiting
Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
Last Updated: February 6, 2009
Condition(s): Melanoma (Skin)
4
Completed
Vaccine Therapy, Incomplete Freund's Adjuvant, and GM-CSF in Treating Patients With HIV
Last Updated: May 1, 2012
Condition(s): Nonneoplastic Condition
5
Completed
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma
Last Updated: April 23, 2011
Condition(s): Leukemia; Lung Cancer; Malignant Mesothelioma; Myelodysplastic Syndromes; Primary Peritoneal Cavity Cancer
6
Completed
Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Last Updated: December 14, 2011
Condition(s): Intraocular Melanoma; Malignant Conjunctival Neoplasm; Melanoma (Skin)
7
Completed
A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant
Last Updated: March 3, 2008
Condition(s): Melanoma
8
Completed
Vaccine Therapy in Treating Patients With Advanced Melanoma
Last Updated: October 12, 2010
Condition(s): Intraocular Melanoma; Malignant Conjunctival Neoplasm; Melanoma (Skin)
9
Completed
A Multicenter, Double-Blind, Phase III, Adjuvant-Controlled Study of the Effect of 10 Units of HIV-1 Immunogen (Remune) Compared to Incomplete Freund's Adjuvant (IFA) Alone Every 12 Weeks on AIDS-Free Survival in Subjects With HIV Infection and CD4 T-Lymphocytes Between 300 and 549 Cells/microL Rega
Last Updated: June 23, 2005
Condition(s): HIV Infections
10
Completed
Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma
Last Updated: February 6, 2009
Condition(s): Melanoma (Skin)
11
Completed
Peptide Vaccine, Montanide ISA 51 and ISA 51 VG, and CpG 7909 in Treating Patients With Resected Stage IIC, Stage III, or Stage IV Melanoma
Last Updated: February 6, 2009
Condition(s): Intraocular Melanoma; Melanoma (Skin)
12
Active, not recruiting
Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma
Last Updated: February 6, 2009
Condition(s): Melanoma (Skin)
13
Active, not recruiting
Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients
Last Updated: March 14, 2012
Condition(s): Melanoma
14
Active, not recruiting
Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome
Last Updated: February 26, 2009
Condition(s): Myelodysplastic Syndromes
15
Completed
Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma
Last Updated: February 6, 2009
Condition(s): Intraocular Melanoma; Melanoma (Skin)
16
Completed
Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery
Last Updated: February 6, 2009
Condition(s): Intraocular Melanoma; Melanoma (Skin)
17
Completed
Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma
Last Updated: February 6, 2009
Condition(s): Melanoma (Skin)
18
Active, not recruiting
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
Last Updated: February 6, 2009
Condition(s): Intraocular Melanoma; Melanoma (Skin)
19
Active, not recruiting
Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
Last Updated: February 6, 2009
Condition(s): Melanoma (Skin)
20
Completed
Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract
Last Updated: February 6, 2009
Condition(s): Colorectal Cancer; Esophageal Cancer; Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Gastric Cancer; Pancreatic Cancer; Small Intestine Cancer

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is: http://clinicaltrialsfeeds.org/clinical-trials/results/?term=Biological+incomplete+Freund+s+adjuvant

Page 1 of Clinical Trials for Biological incomplete Freund s adjuvant, 72 Total Matches

Get the Latest Results via Email or RSS

Subscribe via Web Newsreaders

Browse

Clinical Trials Background

About